Therefore, we postulated that HSP90A inhibition along with anti-PD-1 treatments inflames tumor immune-environments by reversing resistance of immune-refractory tumor cells to T-cell-mediated cytotoxicity. The gene discussed is HSP90AA1; the disease is neoplasm.